News for HCW Biologics Inc. (HCWB)

HCW Biologics earned upfront payment and will recognize revenue of $7.0 million in Q2 2025 MIRAMAR, Fla., June 04, 2025 (GLOBE NEWSWIRE) -- HCW Biologics In

**media[645631]**

HCW Biologics (HCWB) has caught the attention of investors as Maxim Group, with analyst Michael Okunewitch, has issued a new report concerning the stock.Accordi

Maxim has revised its price target for HCW Biologics (HCWB), lowering it from $120 to $35, though the firm maintains a Buy rating on the stock. This adjustment

On May 16, 2025, [Hing Wong](https://www.gurufocus.com/insider/181789/hing-wong), CEO and 10% Owner of HCW Biologics Inc (HCWB), purchased 8,054 shares of the c

MIRAMAR, Fla., May 15, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the ”œCompany” or ”œHCW Biologics”) ( HCWB), a clinical-stage biopharmaceutical comp

Key Highlights: HCW Biologics (HCWB) reported Q1 2025 revenue of $5,065, a steep decline from $1.1 million in Q1 2024.

Key Highlights: HCW Biologics (HCWB) initiates a $5 million follow-on offering, priced at $7.45 per unit. Analysts project considerable upside potential

HCW Biologics (HCWB) has appointed Maxim Group LLC as the exclusive placement agent for its latest offering. This strategic move is part of the company's effort

HCW Biologics (HCWB) announces a $5 million follow-on offering, priced at $7.45 per unit. Proceeds will fund the development of HCW9302 and expand busin

U.S. stocks traded mixed midway through trading, with the Dow Jones index falling around 200 points on Tuesday. The Dow traded down 0.49% to 42,203.63 while th...

U.S. stocks traded higher this morning, with the Nasdaq Composite gaining around 250 points on Monday. The Dow traded down 0.20% to 42,323.48 while the NASDAQ ...

**media[583218]**

HCW Biologics (HCWB) announces a 1-for-40 reverse stock split effective April 11, 2025, to meet Nasdaq's $1.00 minimum bid price requirement.

MIRAMAR, Fla., March 28, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the ”œCompany” or ”œHCW Biologics”) ( HCWB), a clinical-stage biopharmaceutical co

**media[579880]**

Shares of Palantir Technologies Inc. PLTR rose sharply in today's pre-market trading following better-than-expected fourth-quarter results. Palantir reported f...

U.S. stocks traded lower toward the end of trading, with the S&P 500 falling around 0.5% on Monday. The Dow traded down 0.09% to 44,506.60 while the NASDAQ dip...

U.S. stocks traded lower midway through trading, with the Dow Jones index falling around 150 points on Monday. The Dow traded down 0.33% to 44,398.37 while the...